Man Group plc cut its holdings in Medpace Holdings Inc (NASDAQ:MEDP) by 48.0% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 183,017 shares of the company’s stock after selling 169,112 shares during the period. Man Group plc owned about 0.51% of Medpace worth $15,381,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also bought and sold shares of MEDP. Squarepoint Ops LLC lifted its holdings in Medpace by 181.1% in the third quarter. Squarepoint Ops LLC now owns 105,483 shares of the company’s stock worth $8,865,000 after acquiring an additional 67,964 shares during the last quarter. Voloridge Investment Management LLC bought a new position in shares of Medpace during the third quarter valued at approximately $5,921,000. Barclays PLC raised its position in shares of Medpace by 12.3% during the 3rd quarter. Barclays PLC now owns 42,719 shares of the company’s stock worth $3,590,000 after purchasing an additional 4,671 shares during the period. Penserra Capital Management LLC acquired a new stake in shares of Medpace during the 3rd quarter worth approximately $687,000. Finally, California State Teachers Retirement System lifted its holdings in shares of Medpace by 1.2% in the 3rd quarter. California State Teachers Retirement System now owns 43,016 shares of the company’s stock worth $3,615,000 after purchasing an additional 513 shares during the last quarter. 78.87% of the stock is owned by institutional investors and hedge funds.
Shares of Medpace stock opened at $76.55 on Tuesday. Medpace Holdings Inc has a 1-year low of $47.20 and a 1-year high of $86.71. The business’s fifty day moving average price is $74.95 and its two-hundred day moving average price is $71.44. The company has a debt-to-equity ratio of 0.07, a current ratio of 0.80 and a quick ratio of 0.80. The company has a market capitalization of $2.76 billion, a P/E ratio of 26.26, a PEG ratio of 2.10 and a beta of 1.49.
Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Tuesday, October 29th. The company reported $0.71 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.71. The company had revenue of $216.20 million during the quarter, compared to analyst estimates of $217.14 million. Medpace had a net margin of 11.35% and a return on equity of 17.06%. The business’s revenue for the quarter was up 20.6% compared to the same quarter last year. During the same period in the prior year, the business posted $0.67 EPS. On average, research analysts expect that Medpace Holdings Inc will post 2.92 earnings per share for the current fiscal year.
A number of research analysts recently issued reports on MEDP shares. Zacks Investment Research lowered Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, November 2nd. ValuEngine lowered Medpace from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Finally, BidaskClub upgraded Medpace from a “hold” rating to a “buy” rating in a research note on Thursday, November 28th. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $77.00.
In other Medpace news, General Counsel Stephen P. Ewald sold 8,000 shares of the company’s stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $77.30, for a total value of $618,400.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Jesse J. Geiger sold 7,200 shares of the stock in a transaction on Monday, October 14th. The shares were sold at an average price of $78.03, for a total value of $561,816.00. Following the transaction, the chief financial officer now directly owns 40,948 shares of the company’s stock, valued at $3,195,172.44. The disclosure for this sale can be found here. 24.20% of the stock is owned by company insiders.
Medpace Company Profile
Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas.
Featured Story: Conference Calls and Individual Investors
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.